GEN Exclusives

More »

GEN News Highlights

More »
Jun 25, 2007

GPC Biotech Selects Japanese Partner for Satraplatin in $10M Deal

  • Yakult Honsha gained exclusive commercialization rights to GPC Biotech’s satraplatin in Japan for an upfront payment of 1.2 billion yen or $10 million.

    According to the license transaction, Yakult will take the lead in the final development of the drug in Japan. Satraplatin has shown statistically significant improvement in progression-free survival in Phase III investigations as a treatment for hormone refractory prostate cancer and its NDA is scheduled to be reviewed by an advisory committee on July 24.

    In addition to the upfront fee, Yakult will also make payments based on the achievement of certain regulatory filing and approval milestones. GPC Biotech will also receive a minimum of 21% royalties on sales in Japan.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?